PIN1-targeted therapy for pancreatic cancer
Official title: Project 2
Funded at Beckman Research Institute/city of Hope · NIH-11626518 · Data updated 2026-11-12
A team is developing new PIN1 inhibitors to treat pancreatic cancer that tends to resist current therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project start | September 22, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $176,000 |
| NIH project number | 5U54CA285116-04 |
| Project ID | NIH-11626518 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with pancreatic cancer or those who could contribute to related translational studies may be considered in later phases or companion studies.
✕Less likely to help
Patients with pancreatic cancer not responding to PIN1-targeted therapy or with contraindications to investigational agents may not experience benefit.
What this research studies
This project focuses on creating and refining new drug-like compounds that block PIN1, a protein that helps pancreatic cancer grow and shape a suppressive tumor environment. The work combines chemistry, cell-based tests, and animal studies to understand how these inhibitors work and how well they reach tumors. If successful, the best agents will be tested for their ability to slow cancer growth and improve responses to other treatments. The collaboration between UC Riverside and City of Hope aims to translate lab findings into potential new treatment options for patients with pancreatic cancer.
Why it matters
Potential benefit: If successful, patients with pancreatic cancer could gain a new therapeutic option that targets the tumor’s signaling pathways and may enhance response to other treatments.
How similar studies have gone: PIN1 inhibitors have shown preclinical promise in pancreatic cancer models, supporting the potential but remaining early-stage.
Where this research is happening
-
Beckman Research Institute/city of Hope
Duarte, United States Active
Researchers
- Principal investigator: Raoof, Mustafa — Beckman Research Institute/city of Hope
- Study coordinator: Raoof, Mustafa
Related research
Other NIH-funded projects on the same topics.
-
Targeting the protein-assembly that drives AML growth
Aiming to slow or stop acute myeloid leukemia by blocking how cancer cells make proteins.
-
Metformin for reversing accelerated aging in young adults with metabolic health issues
A practical plan to use metformin to help 18- to 35-year-olds with insulin resistance improve metabolic health and slow aging.
-
DNA mismatch repair defects and anti-tumor immunity in cancer
Researchers are studying how defects in a DNA repair system affect the body’s immune response to tumors, to improve cancer treatments that use the immune system.
-
Understanding how skin cancer-associated fibroblasts affect immune detection in early mycosis fungoides
This grant investigates how certain skin cells in early mycosis fungoides might help the cancer hide from the immune system, with findings aiming to improve future patient care.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Integrated Islet Distribution Program supports access to human pancreatic islets for diabetes research
This grant helps provide researchers with human pancreatic islets and related tissues to study diabetes, aiming to accelerate better understanding and treatments for adults with diabetes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.